From: Immune characterization of breast cancer metastases: prognostic implications
 | TILs %, median (Q1 – Q3): all patients 5 (2–10) | |||||
---|---|---|---|---|---|---|
Overall | p value | TN | p value | HER2+ | p value | |
Tumor phenotype | ||||||
 TN | 5 (2–10) |  | – |  | – |  |
 HER2+ | 5 (2–11) | 0.855 | – | – | – | – |
Age at BC diagnosis | ||||||
  ≤ 50 years | 3 (2–8) | 0.002 | 3 (2–10) | 0.037 | 4 (2–8) | 0.010 |
  > 50 years | 8 (5–15) | 7 (4–11) | 9 (5–18) | |||
HR status | ||||||
 Negative | – | – | – | – | 9 (5–15) | 0.029 |
 Positive | – | – | 4 (2–8) | |||
Organ/site of biopsy | ||||||
Liver | 5 (2–8) | 0.277 | 5 (5–11) | 0.936 | 5 (2–8) | 0.119 |
Skin | 3(2–10) | 3 (2–10) | 4 (2–10) | |||
Lung | 9 (5–18) | 8 (3–10) | 18 (6–19) | |||
CNS | 6 (3–11) | 4 (3–38) | 11 (5–11) | |||
Other | 5 (2–8) | 5 (2–19) | 5 (2–8) | |||
Pre-biopsy systemic treatment for MBC | ||||||
 No | 5 (3–11) | 0.563 | 5 (3–10) | 0.104 | 4 (2–13) | 0.652 |
 Yes | 5 (2–8) | 2 (2–5) | 6 (5–9) |